City Therapeutics
PublicCity Therapeutics is now publicly traded
The data on this page reflects City Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Series B
Jun 8, 2026
Total Funding Raised
$264.5M
Company Overview
City Therapeutics is a biotechnology company that develops next-generation RNA interference (RNAi) therapeutics designed to silence disease-causing genes by targeting and degrading messenger RNA.
Sector
Biotech
Verticals
Life Sciences
AI Layer
Non-AI
Keywords
City Therapeutics Comparables
Compare City Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Soufflé Therapeutics | 86% | |
| Sanegene Bio | 84% | |
| Arexera Therapeutics | 83% |
City Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 8, 2026 | ||||
| Convertible Debt | May 27, 2025 | ||||
| Series A | Oct 8, 2024 |
City Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Fidelity Management & Research Company | Series B, Series A |
| Invus Opportunities | Series B |
| ARCH Venture Partners | Series B, Series A |
| Viking Global Investors | Series B |
| AN Venture Partners | Series B, Series A |
| Casdin Capital | Series B |
| Rock Springs Capital | Series B, Series A |
Recent news
Latest coverage and updates
- goes_publicSep 24, 2026
Citytx files for a U.S. initial public offering on Sep 24th '26, seeking additional funding for its RNA interference drug programs.
- hiresAug 11, 2026
Citytx appoints Mary Beth DeLena, J.D., as Chief Legal Officer to oversee legal affairs and corporate governance in Massachusetts on Aug 11th '26.
- hiresAug 11, 2026
Citytx appoints Keith Regnante, MBA, as Chief Financial Officer to lead its finance organization and capital strategy in Massachusetts on Aug 11th '26.
City Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access